nChroma Bio
Advancing targeted genetic medicine with safe, precise in vivo delivery, focusing on liver therapies like CRMA-1001 to address chronic hepatitis B and D using epigenetics.
Employees
Enterprise value
$300—450m
Authorizing premium user...
Advancing targeted genetic medicine with safe, precise in vivo delivery, focusing on liver therapies like CRMA-1001 to address chronic hepatitis B and D using epigenetics.